Literature DB >> 16521178

Liver cirrhosis and arterial hypertension.

Jens H Henriksen1, Soren Moller.   

Abstract

Characteristic findings in patients with cirrhosis are vasodilatation with low overall systemic vascular resistance, high arterial compliance, increased cardiac output, secondary activation of counter-regulatory systems (renin-angiotensin-aldosterone system, sympathetic nervous system, release of vasopressin), and resistance to vasopressors. The vasodilatory state is mediated through adrenomedullin, calcitonin gene-related peptide, nitric oxide, and other vasodilators, and is most pronounced in the splanchnic area. This constitutes an effective (although relative) counterbalance to increased arterial blood pressure. This review considers the alterations in systemic hemodynamics in patients with cirrhosis in relation to essential hypertension and arterial hypertension of the renal origin. Subjects with arterial hypertension (essential, secondary) may become normotensive during the development of cirrhosis, and arterial hypertension is rarely manifested in patients with cirrhosis, even in cases with renovascular disease and high circulating renin activity. There is much dispute as to the understanding of homoeostatic regulation in cirrhotic patients with manifest arterial hypertension. This most likely includes the combination of vasodilatation and vasoconstriction in parallel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16521178      PMCID: PMC4066115          DOI: 10.3748/wjg.v12.i5.678

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  49 in total

1.  Hormonal aspects of the relation of liver cirrhosis to essential hypertension.

Authors:  F Veglio; G Pinna; R Melchio; F Rabbia; M Panarelli; D Schiavone; P Mulatero; L Chiandussi
Journal:  Clin Exp Hypertens A       Date:  1992

2.  An evaluation of hypertension and liver disease in an alcoholic service.

Authors:  H F LOYKE; R CUTARELLI
Journal:  Am J Med Sci       Date:  1960-09       Impact factor: 2.378

3.  Reduction of hypertension after liver disease.

Authors:  H F LOYKE
Journal:  Arch Intern Med       Date:  1962-07

Review 4.  Vasoactive substances in the circulatory dysfunction of cirrhosis.

Authors:  S Møller; F Bendtsen; J H Henriksen
Journal:  Scand J Clin Lab Invest       Date:  2001       Impact factor: 1.713

5.  Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique.

Authors:  M Kiszka-Kanowitz; J H Henriksen; S Møller; F Bendtsen
Journal:  J Hepatol       Date:  2001-11       Impact factor: 25.083

6.  Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-02-26       Impact factor: 4.052

7.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 8.  Hepatorenal syndrome.

Authors:  Pere Ginès; Mónica Guevara; Vicente Arroyo; Juan Rodés
Journal:  Lancet       Date:  2003-11-29       Impact factor: 79.321

9.  Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease.

Authors:  Kim Brinch; Søren Møller; Flemming Bendtsen; Ulrik Becker; Jens H Henriksen
Journal:  J Hepatol       Date:  2003-07       Impact factor: 25.083

10.  Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics.

Authors:  S Møller; V Gülberg; J H Henriksen; A L Gerbes
Journal:  J Hepatol       Date:  1995-08       Impact factor: 25.083

View more
  15 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.

Authors:  Ahmed A Magan; Atif A Khalil; Mohamed H Ahmed
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

3.  Vasopressin deficiency and vasodilatory state in end-stage liver disease.

Authors:  Gebhard Wagener; Galina Kovalevskaya; Moury Minhaz; Fallon Mattis; Jean C Emond; Donald W Landry
Journal:  J Cardiothorac Vasc Anesth       Date:  2010-12-03       Impact factor: 2.628

Review 4.  Hypertension Induced Morphological and Physiological Changes in Cells of the Arterial Wall.

Authors:  Patricia Martinez-Quinones; Cameron G McCarthy; Stephanie W Watts; Nicole S Klee; Amel Komic; Fabiano B Calmasini; Fernanda Priviero; Alexander Warner; Yu Chenghao; Camilla F Wenceslau
Journal:  Am J Hypertens       Date:  2018-09-11       Impact factor: 2.689

5.  Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.

Authors:  Walkíria Wingester Vilas-Boas; Antônio Ribeiro-Oliveira; Renata da Cunha Ribeiro; Renata Lúcia Pereira Vieira; Jerusa Almeida; Ana Paula Nadu; Ana Cristina Simões e Silva; Robson Augusto Souza Santos
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

6.  Altered central TRPV4 expression and lipid raft association related to inappropriate vasopressin secretion in cirrhotic rats.

Authors:  Flávia Regina Carreño; Lisa L Ji; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-17       Impact factor: 3.619

7.  Very High Dose Epinephrine for the Treatment of Vasoplegic Syndrome during Liver Transplantation.

Authors:  M B Khosravi; S Milani; S Ghaffaripour; A Sahmeddini; M H Eghbal; S A Malek-Hosseini
Journal:  Int J Organ Transplant Med       Date:  2013

8.  Characterization of pressure-mediated vascular tone in resistance arteries from bile duct-ligated rats.

Authors:  Ravirajsinh N Jadeja; Menaka C Thounaojam; Sandeep Khurana
Journal:  Oncotarget       Date:  2017-05-09

9.  Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents.

Authors:  Jung-Ho Shin; Hee Jin Kwon; Hye Ryoun Jang; Jung Eun Lee; Geum-Youn Gwak; Wooseong Huh; Sin-Ho Jung; Joon Hyeok Lee; Yoon-Goo Kim; Dae Joong Kim; Ha Young Oh
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

10.  One-Year Mortality after Traumatic Brain Injury in Liver Cirrhosis Patients--A Ten-Year Population-Based Study.

Authors:  Chieh-Yang Cheng; Chung-Han Ho; Che-Chuan Wang; Fu-Wen Liang; Jhi-Joung Wang; Chung-Ching Chio; Chin-Hung Chang; Jinn-Rung Kuo
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.